Regeneron Pharmaceuticals, Inc.

Regeneron has outlined a credible path to $17B in annual Dupixent sales, supported by multiple label expansions and robust clinical momentum. The drug continues to drive earnings beats, with the company posting three consecutive quarters of outperformance, reinforcing confidence in the franchise's durability.

Intensifying competition in the atopic dermatitis space from rivals such as AbbVie raises concerns about Dupixent's long-term market share and pricing power. Cantor Fitzgerald specifically cited Dupixent performance relative to consensus as a reason for cutting its price target, signaling potential revenue disappointment.

Eylea HD remains a meaningful commercial contributor alongside Dupixent, helping Regeneron sustain a 29.65% net income margin and $4.50B net income in 2025. The franchise's resilience supports confidence that the ophthalmology segment can weather near-term headwinds without materially impairing overall earnings.

Cantor Fitzgerald reduced its price target from $785 to $750, explicitly flagging concerns around Eylea HD and SD performance versus consensus expectations. This suggests analysts are increasingly skeptical that the ophthalmology franchise can sustain its historical revenue contribution as competition from biosimilars and alternative therapies intensifies.

With a consensus average 12-month price target of $819.18, representing over 21% upside from current levels, the majority of the 26 analysts covering Regeneron rate it a Buy. Firms like TD Cowen and Piper Sandler have targets as high as $960 and $854 respectively, reflecting conviction in the pipeline and earnings power.

Despite the broadly positive consensus, Morgan Stanley and RBC Capital maintain Hold ratings with notably lower price targets of $730 and $696, well below the consensus average. This wide target dispersion — from $641 to $1,000 — reflects genuine disagreement about whether the stock's current valuation already prices in pipeline success and near-term growth.